Limits for the scaled average bioequivalence of highly variable drugs and drug products.
- 1 January 2003
- journal article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 20 (3), 382-389
- https://doi.org/10.1023/a:1022695819135
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products.European Journal of Clinical Pharmacology, 2001
- Statistical issues in bioequivalanceStatistics in Medicine, 2001
- Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies.International journal of clinical pharmacology and therapeutics, 2001
- Individual Bioequivalence RevisitedClinical Pharmacokinetics, 2001
- A practical approach for evaluating population and individual bioequivalenceStatistics in Medicine, 2000
- PhRMA Perspective on Population and Individual BioequivalenceThe Journal of Clinical Pharmacology, 2000
- Indexes of contrast and quantitative significance for comparisons of two groupsStatistics in Medicine, 1999
- Individual bioequivalence: attractive in principle, difficult in practice.Pharmaceutical Research, 1998
- Individual BioequivalenceClinical Pharmacokinetics, 1997
- Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.1996